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Besides their role in desensitization,b-arrestin 1 and 2
promote the formation of signaling complexes al-
lowing G protein-coupled receptors (GPCR) to signal
independently from G proteins. Here we show that
lithium, a pharmacological agent used for the man-
agement of psychiatric disorders such as bipolar dis-
order, schizophrenia, and depression, regulates Akt/
glycogen synthase kinase 3 (GSK3) signaling and
related behaviors in mice by disrupting a signaling
complex composed of Akt, b-arrestin 2, and protein
phosphatase 2A. When administered to b-arrestin 2
knockout mice, lithium fails to affect Akt/GSK3 signal-
ing and induce behavioral changes associated with
GSK3 inhibition as it does in normal animals. These re-
sults point toward a pharmacological approach to
modulating GPCR function that affects the formation
of b-arrestin-mediated signaling complexes.
INTRODUCTION
The scaffolding proteins b-arrestin 1 and b-arrestin 2 (bArr2) have
been traditionally associated with the termination of G protein-cou-
pled receptor (GPCR) signaling and with receptor desensitization
(Ferguson et al., 1996; Lohse et al., 1989). Following stimulation,
GPCRs are rapidly phosphorylated by members of a family of
GPCR kinases (GRKs) (Premont and Gainetdinov, 2007). The phos-
phorylationof receptorsbyGRKs leads tob-arrestin recruitment, re-
sulting in the uncoupling of the receptors fromG proteins and GPCR
internalization. However, evidence obtained from cell culture sys-
tems (Luttrell et al., 1999; Ahn et al., 2004) has shown that b-arrest-
ins also act as scaffolds for the formation of signaling protein com-
plexes allowing GPCRs to signal independently from G proteins.
We have recently shown in vivo that the Akt/glycogen syn-
thase kinase 3 (GSK3) signaling cascade can be regulated bya signaling complex scaffolded by bArr2 (Beaulieu et al.,
2005, 2007a). Akt is a serine/threonine kinase regulated by
phosphatidylinositol kinase (PI3K)-mediated signaling. Activa-
tion of Akt involves phosphorylation of a regulatory threonine
residue (Thr308) by phosphatidylinositol-dependent kinase 1
(PDK1) and additional phosphorylation of Ser473 by the
PDK2/TORC2 kinase (Alessi and Cohen, 1998; Jacinto et al.,
2006). In turn, activated Akt phosphorylates GSK3b, a constitu-
tively active kinase, on the Ser 9 residue and renders it inactive
(Cross et al., 1995).
Stimulation of the dopamine (DA) D2 receptor (D2R), a proto-
typical GPCR, in the mouse striatum results in Akt inactivation
and concomitant activation of GSK3b (Beaulieu et al., 2004,
2006, 2007b). Importantly, bArr2 is essential for the regulation
of Akt and GSK3 by D2R. Activation of this GPCR by tonic DA
and/or dopaminergic drugs leads to the formation of a signaling
complex composed of Akt, bArr2, and the protein phosphatase
2A (PP2A), which dephosphorylates/inactivates Akt, as demon-
strated pharmacologically (Beaulieu et al., 2005). Furthermore,
regulation of the Akt/GSK3 signaling by bArr2 plays an important
role for the expression of behavioral responses to DA or drugs
such as amphetamine, which act on DA neurotransmission
(Beaulieu et al., 2005; Gainetdinov et al., 2004).
Modulation of Akt/GSK3 signaling by lithium also antagonizes
the development of DA-dependent behaviors in rodents (Beau-
lieu et al., 2004; Cox et al., 1971). Lithium is commonly used in
the management of mood disorders along with drugs targeting
central monoaminergic transmission (Phiel and Klein, 2001; Va-
lenstein et al., 2006). Although multiple molecular targets of lith-
ium have been identified (Berridge et al., 1989; Klein and Melton,
1996), the mechanisms by which this agent exerts its therapeutic
actions are still not well understood (Phiel and Klein, 2001).
Among other actions, lithium can inhibit GSK3 either directly
(Klein and Melton, 1996) or indirectly by increasing its Akt-medi-
ated inhibition (Beaulieu et al., 2004; Chalecka-Franaszek and
Chuang, 1999; De Sarno et al., 2002). Furthermore, pharmaco-
logical or genetic inhibition of GSK3b in rodents recapitulates
some of the effects of lithium on behavior (Beaulieu et al.,Cell 132, 125–136, January 11, 2008 ª2008 Elsevier Inc. 125
Figure 1. bArr2 Is Required for the Modulation of Akt/GSK3 Phosphorylation in Response to Acute Lithium Administration
(A–C) Western blot (A) and densitometric analysis (B and C) of relative levels of phospho-Thr308-Akt and phospho-Ser9-GSK3b in extracts prepared from the
striatum of WT or bArr2-KO mice 30 min after injection of LiCl (200 mg/kg, i.p.). Representative western blots show results obtained from two separate striatal
extracts prepared from different mice for each group. For densitometric analysis 10 mice per group were used.
(D) Densitometric analysis of relative levels of phospho-Ser9-GSK3b from western blots prepared from the striatum of WT (C57BL/6) mice treated with LiCl (50 or
100 mg/kg, i.p.) (n = 5 mice per group).
(E) Basal phosphorylation of Akt and GSK3b in the striatum of bArr2-KO mice as compared to WT littermates (n = 5 per group).
(F) Basal levels of Akt and GSK3b in striatal extract from drug-naive bArr2-KO and WT littermates (n = 5 mice per group).
(G–J) Western blots (G and I) and densitometric analysis (H and J) of phospho-Thr308-Akt and phospho-Ser9-GSK3b in the striatum of WT or bArr2-KO mice 30
min after ICV injection of either vehicle or 5 ml of a 5 mM pbV (phen) solution.
Total kinase levels in extracts were used as loading controls for measurement of phospho-protein levels while b-actin was used as a loading control in (F). Data are
means ± SEM; *p% 0.05, ***p% 0.005, two-tailed Student’s t test.2004; Gould et al., 2004; O’Brien et al., 2004), whereas overex-
pression of this kinase in mice reproduces behavioral correlates
of hyperactivity and mania (Prickaerts et al., 2006).
Here we provide evidence for the involvement of the Akt:
bArr2:PP2A signaling complex in the pharmacological actions
of lithium in vivo, thus indicating that b-arrestin signaling com-
plexes may represent a target for drug intervention aimed at
the regulation of GPCR signaling.126 Cell 132, 125–136, January 11, 2008 ª2008 Elsevier Inc.RESULTS
Regulation of Akt/GSK3 Phosphorylation
by Lithium Requires b-arrestin 2
To investigate the actions of lithium on the Akt:bArr2:PP2A sig-
naling complex, wild-type (WT) and bArr2-KO mice were treated
with lithium under conditions shown to activate brain Akt and af-
fect behavior without toxicity in rodents (Beaulieu et al., 2004).
Figure 2. Role of bArr2 in GSK3b-Mediated Inhibition
of Novelty-Induced Locomotor Activity in Response
to Acute Lithium Treatment
(A) Disrupted effect of lithium on locomotor activity in a novel
environment in bArr2-KO mice. Animals (bArr2-KO or WT litter-
mates) were treated with LiCl (100 or 200 mg/kg, i.p.) or vehicle
and placed in a locomotor activity monitor for a period of
30 min post-injection (n = 8 mice per group).
(B) Effect of ICV lithium injections (5 ml of a 75 mM solution) on
novelty-induced locomotor activity in bArr2-KO mice and WT
littermates. Locomotor activity was monitored for a period of
30 min starting 5 min after ICV injection. Note that for each
genotype the stress associated with ICV injection resulted in
enhanced locomotor activities and reduced the effect of the
bArr2-KO genotype on basal locomotion in vehicle-treated an-
imals (n = 8 mice per group).
(C) Enhanced inhibition of locomotor activity in a novel envi-
ronment by lithium in gsk3b+/ mice. Mice (gsk3b+/ or WT lit-
termates) were treated with vehicle or 100 mg/kg lithium (i.p.)
and locomotor activity was monitored for a period of 30 min
after injection (n = 9 to 10 mice per group).
(D) The GSK3 inhibitor TDZD-8 (30 mg/kg, i.p.) inhibits loco-
motor activity in a novel environment in both bArr2-KO and
WT littermates injected with vehicle or TDZD-8 (n = 7 to 12
mice per group).
(E) TDZD-8 does not inhibit locomotor activity in habituated WT
mice. Followinga 1 hrhabituation period in the locomotoractivity
monitor, mice were injected with vehicle or TDZD-8 (30 mg/kg,
i.p.) and locomotion was monitored (n = 6 to 9 mice per group).
(F) Schematic representation of the bArr2/PP2A/Akt/GSK3
signaling pathway indicating the direct and indirect—bArr2-
mediated—inhibitory action of lithium on GSK3 and direct
inhibition of GSK3 by TDZD-8. Red lines indicate inhibitory
actions.
For all tests, locomotion was measured as total distance trav-
eled for the duration of the test (30 min); data are means ±
SEM; *p % 0.05 vehicle versus lithium or TDZD within geno-
type; ***p % 0.005 vehicle versus lithium within genotype;
#p % 0.05, bArr2-KO or gsk3b+/ mice versus WT mice re-
ceiving the same treatment. ANOVA was followed by Bonfer-
roni tests.Administration of lithium (200 mg/kg i.p.), which produces brain
concentrations of lithium of 1 mM (see Table S1 available on-
line), to WT mice increased striatal levels of phospho-Akt and
phospho-GSK3b (Figures 1A–1C). A similar increase of striatal
GSK3b phosphorylation in WT mice was also evident with
100 mg/kg lithium (Figure 1D). Incontrast,administrationof lithium
to bArr2-KO mice resulted in a minor reduction in striatal phospho-
Akt and did not affect phospho-GSK3b levels (Figures 1A–1C).
Comparison of basal phospho-Akt and phospho-GSK3b levels
in WT and bArr2-KO mice showed that a lack of bArr2 markedly
increased the phosphorylation of these kinases without changing
their overall levels (Figures 1E and 1F). These data are consistent
with a contribution of bArr2 in the regulation of Akt by PP2A in
mice having a normal dopaminergic tone (Beaulieu et al., 2005).
However, since bArr2 may affect many signaling pathways it is
important to verify if it is still possible to increase the phosphory-
lation of Akt and GSK3b inbArr2-KO mice in response to PI3K sig-
naling. To assess this, we used bis peroxovanadium 1,10-phe-
nanthroline (bpV(phen)), a potent activator of PI3K signaling
that enhances Akt and GSK3b phosphorylation in cells (Lavoie
et al., 1999). As shown (Figures 1G–1J), intracerebroventricular(icv) injection of bpV(phen) to either WT orbArr2-KO mice resulted
in an increased phosphorylation of both Akt and GSK3b in the
striatum of these mice. Taken together these data indicate that
bArr2 is essential for the regulation of Akt and GSK3b phosphor-
ylation by lithium but not by PI3K-mediated signaling.
GSK3b and b-arrestin 2 Mediate Behavioral
Effects of Lithium
We then proceeded to investigate the contribution of bArr2 to the
acute behavioral responses to lithium. Inhibition of locomotor
activity in a novel environment, a documented behavioral effect
of acute lithium treatment (Beaulieu et al., 2004), was evaluated
in WT and bArr2-KO mice. In nonhabituated WT mice, LiCl (100
or 200 mg/kg, i.p.) caused a dose-dependent inhibition of hori-
zontal activity (Figure 2A). As previously reported (Beaulieu
et al., 2005), bArr2-KO mice displayed reduced horizontal activ-
ity as compared to WT littermates when placed in a novel envi-
ronment (Figure 2A). However, administration of LiCl to bArr2-
KO mice did not affect horizontal activity (Figure 2A). LiCl was
also administered by ICV injection under conditions known not
to elicit peripheral responses to lithium in rodents (Smith,Cell 132, 125–136, January 11, 2008 ª2008 Elsevier Inc. 127
1980). In line with results obtained following systemic lithium ad-
ministration, ICV lithium injections provoked a marked reduction
of locomotor activity in WT mice while having no effect in bArr2-
KO mice (Figure 2B), thus demonstrating that bArr2-dependent
behavioral effects of lithium are centrally mediated.
To assess the involvement of GSK3b in this action of lithium on
behavior, GSK3b haploinsufficient mice (gsk3b+/) (Hoeflich et al.,
2000) were also tested. As shown (Figure 2C), vehicle-treated
gsk3b+/ and WT littermates exhibited comparable locomotor
activity in a novel environment. However, administration of LiCl
(100 mg/kg i.p.) had a more pronounced effect on locomotion in
gsk3b+/ than in WT mice, thus supporting the involvement of
GSK3b inhibition in the locomotor-suppressing action of lithium.
To further examine the contribution of GSK3b, we used direct
pharmacological inhibition of GSK3 with the blood brain barrier-
permeable GSK3b inhibitor thiadiazolidinone (TDZD-8) (Beaulieu
et al., 2004; Martinez, 2006). Administration of TDZD-8 (30 mg/kg
i.p.) to WT mice led to a reduction of novelty-induced horizontal
activity comparable to that observed following lithium administra-
tion (Figure 2D). To address the possibility of a nonspecific toxic
action of TDZD-8 we also administered this drug to habituated
animals and monitored activity. Importantly, the effect of TDZD-8
on locomotion was specific to novelty-induced locomotor activity
since this drug had no effect in habituated mice (Figure 2E).
Lithium can inhibit GSK3b both directly (Klein and Melton,
1996) and indirectly by enhancing Akt activity (Beaulieu et al.,
2004; Chalecka-Franaszek and Chuang, 1999). To address the
relative contributions of these mechanisms we treated bArr2-
KO mice with TDZD-8 to evaluate whether direct inhibition of
GSK3b can affect novelty-induced locomotor activity in these
mice. TDZD-8 (30 mg/kg, i.p.) produced a reduction of horizontal
Figure 3. Role of bArr2 in the GSK3b-Mediated ‘‘Anti-
depressant-like’’ Effects of Acute Lithium Treatment
(A) Tail suspension test in WT and in bArr2-KO mice following
injection of vehicle or LiCl (50, 75, or 100 mg/kg, i.p.) (n = 10 to
14 mice per group).
(B) Tail suspension test in WT or gsk3b+/ mice following injec-
tionofvehicle orLiCl (100mg/kg, i.p.) (n= 7 to 10micepergroup).
(C)Dark-lightemergence test inWTand inbArr2-KOmicefollow-
ing injection of vehicle or LiCl (75 mg/kg, i.p.) (n = 8 mice per
group).
(D) Dark-light emergence test in WT mice following injection of
vehicle or TDZD-8 (10 mg/kg, i.p.) (n = 6 to 7 mice per group).
For tail suspension, behavior was scored as time spent in im-
mobility (s) for the whole duration of the test (6 min); for dark-
light emergence, behavior was scored as the latency to cross
from the dark to the light compartment of the test chamber.
For all tests, data are means ± SEM; *p% 0.05 vehicle versus
lithium or TDZD within genotype; **p% 0.01, ***p% 0.005 vehi-
cle versus lithium within genotype; #p % 0.05, ## p % 0.01
bArr2-KO or gsk3b+/ mice versus WT mice receiving the
same drug treatment.ANOVAwas followedby Bonferroni tests.
activity in bArr2-KO mice resulting in activity levels
comparable to those obtained with this drug in WT
mice (Figure 2D). This indicates that novelty-in-
duced locomotor activity can be further sup-
pressed by a direct inhibition of GSK3 in mice lack-
ing bArr2. Thus, the absence of a lithium effect on
locomotion in bArr2-KO mice likely reflects a disruption of the
indirect, Akt-mediated, inhibitory action of lithium on GSK3b
(Figure 2F).
Apart from their action on locomotion, lithium and GSK3 inhib-
itors also have effects on behavioral paradigms used to evaluate
the action of antidepressants in mice (Gould et al., 2004; O’Brien
et al., 2004). Reduction of immobility times in the tail suspension
test is a paradigm commonly used to evaluate ‘‘antidepressant-
like’’ effects of drugs in rodents (Crowley et al., 2004). A first set
of tests showed that acute administration of different doses of
LiCl reduces immobility in WT mice (Figures 3A and 3B) and
that GSK3b haploinsufficiency phenocopies this behavioral
effect (Figure 3B). Furthermore administration of lithium to
gsk3b+/mice resulted in more pronounced reduction of immobil-
ity than in WT littermates (Figure 3B), thus supporting a role for
GSK3b inhibition in the ‘‘antidepressant-like’’ action of lithium.
To further establish the involvement of bArr2 in behavioral re-
sponses to lithium we performed the tail suspension test follow-
ing acute LiCl administration to bArr2-KO mice. As shown
(Figure 3A), while LiCl (75 or 100 mg/kg i.p.) caused pronounced
reductions of immobility time in WT mice, these same treatments
failed to induce significant changes in bArr2-KO mice.
Measurement of the latency to cross from a dark compartment
to an illuminated one in the dark-light emergence test is a simple
behavioral assay used to assess the anxiolytic efficacy of antide-
pressants and anxiolytics in rodents (Crawley and Goodwin,
1980; Weisstaub et al., 2006). As shown in Figure 3C, acute lith-
ium treatment markedly reduces the latency to cross in WT ani-
mals. Furthermore, pharmacological inhibition of GSK3b with
TDZD-8 exerts a similar effect in these mice, thus suggesting
a contribution of GSK3-mediated signaling events in this effect128 Cell 132, 125–136, January 11, 2008 ª2008 Elsevier Inc.
Figure 4. Disruption of the Akt:bArr2:PP2A
Signaling Complex by Lithium In Vitro and
In Vivo
(A) Coimmunoprecipitation of PP2A C subunit
along with Akt in striatal extracts prepared from
WT littermates but not bArr2-KO mice.
(B) Disruption of the Akt interaction with bArr2 and
PP2A by lithium in vitro. Striata from drug-naive
WT (C57BL/6) mice were homogenized in lysis
buffer containing various concentrations of LiCl
(0 to 10 mM) and used in the Akt coimmunopreci-
pitation.
(C) Coimmunoprecipitation of PP2A B subunit with
the PP2A C subunit or Akt in the presence or ab-
sence of lithium in vitro. The PP2A B subunit was
immunoprecipitated from striatal extracts pre-
pared from drug-naive WT mice using lysis buffer
with or without LiCl (1 mM).
(D) Coimmunoprecipitation of PP2A C subunit
along with Akt in striatal extracts prepared from
drug-naive WT mice using lysis buffer without
added salt (‘‘salt-free’’) or buffers containing either
KCl (20 mM), NaCl (20 or 100 mM), CaCl2 (20 mM),
LiCl (20 mM), or MgCl2 (20 mM).
(E) Disruption of the Akt:PP2A bArr2-mediated in-
teraction in vivo. Coimmunoprecipitations were
carried out in lithium-free lysis buffer using striatal
extracts obtained from WT mice 30 min following
administration of saline (S) or lithium (200 mg/kg,
i.p.) (Li). H: control striatal homogenate.
(F) Coimmunoprecipitation of PP2A C subunit
along with Akt in striatal extracts prepared from
drug-naive WT mice using lysis buffer without added salts or buffer containing LiCl (1 mM) or LiCl along with various competing salts: KCl, MgCl2, or NaCl at
a 20 mM concentration.
(G) GST pulldown showing interaction of recombinant phospho-Akt1 with a GST-bArr2 recombinant protein.
(H) Salt-dependent coimmunoprecipitation of purified GST-bArr2 recombinant protein with recombinant phospho-Akt1. Purified proteins were incubated in in-
teraction buffers containing either no added salts, MgCl2 (20 mM), LiCl (50 mM), or a combination of these salts. All experiments were replicated at least three
times.of acute lithium (Figure 3D). However, acute administration of
LiCl (75 mg/kg) had no effect on this behavioral paradigm in
bArr2-KO mice (Figure 3C). Taken together, these observations
demonstrate that bArr2 is an important determinant of the
regulation of behavior by acute lithium and suggest that this
compound may exert part of its actions by interfering with the
regulation of Akt and GSK3b by the Akt:bArr2:PP2A signaling
complex.
Lithium Disrupts the Akt:bArr2:PP2A
Signaling Complex In Vitro
The observation that immunoprecipitation of Akt from striatal ex-
tracts led to a coimmunoprecipitation of the endogenous cata-
lytic C subunit of PP2A in WT mice but not in bArr2-KO mice
(Figure 4A) indicates that bArr2 is an essential scaffold for the in-
teraction of these two signaling proteins in the mouse striatum
(Beaulieu et al., 2005). We next investigated the effect of lithium
on the stability of the Akt:bArr2:PP2A signaling complex. In a first
set of in vitro experiments, Akt immunoprecipitations were per-
formed using striatal extracts from nontreated WT mice with lysis
buffers containing various lithium concentrations (0 to 10 mM).
These experiments revealed a destabilization of the Akt:bArr2
and Akt:PP2A C subunit interactions in lysis buffers containingLiCl concentrations greater than 0.5 mM (Figure 4B), thus sug-
gesting that at these concentrations lithium can destabilize pre-
assembled Akt:bArr2:PP2A signaling complexes in vitro.
To further test this possibility, immunoprecipitations using an-
tibodies directed against the B subunit of PP2A were carried out
in the presence of 1 mM LiCl. PP2A is a multimeric protein com-
plex composed of a structural A subunit, a catalytic C subunit,
and one of a variety of targeting B subunits (Janssens and Goris,
2001). Consistent with previous results, lithium prevented the im-
munoprecipitation of Akt with the targeting B subunit of PP2A
(Figure 4C). In contrast, it did not affect the interaction of PP2A
B and C subunits, thus indicating that lithium disrupts the Akt:
bArr2:PP2A signaling complex without affecting the integrity of
PP2A.
To rule out the possibility that increased salt concentrations
may nonspecifically affect the integrity of the complex, immuno-
precipitations were carried out in the presence of higher concen-
trations of various chloride salts. As shown (Figure 4D), in con-
trast to LiCl (20 mM), other salts, KCl (20 mM), NaCl (20 and
100 mM), CaCl2 (20 mM), or MgCl2 (20 mM) did not markedly
affect the bArr2-mediated interaction of Akt and PP2A, thus
suggesting a selective role of lithium in destabilizing the Akt:
bArr2:PP2A complex.Cell 132, 125–136, January 11, 2008 ª2008 Elsevier Inc. 129
Disruption of the Akt:bArr2:PP2A Complex
by Lithium In Vivo
To examine the effect of lithium on the Akt:bArr2:PP2A com-
plex in vivo, we performed coimmunoprecipitations using a lith-
ium-free lysis buffer and striatal extracts obtained from LiCl
(200 mg/kg, i.p.) or vehicle-treated WT mice at 30 min post-injec-
tion. As shown (Figure 4E), lithium treatment prevented the
bArr2-dependent interaction of Akt and PP2A, indicating that
lithium also destabilizes the Akt:bArr2:PP2A signaling complex
in vivo.
Lithium/Magnesium Competition
Destabilizes the Akt:bArr2 Interaction
It has been suggested that lithium may exert some of its pharma-
cological effects by competing with magnesium, a cofactor of
multiple enzymes including kinases such as GSK3 (Birch,
1974; Ryves and Harwood, 2001). To explore the possible
involvement of a lithium/magnesium competition on the destabi-
lization of Akt:bArr2:PP2A complexes, coimmunoprecipitations
were carried out using lysis buffers containing both lithium and
various other cations. Remarkably, MgCl2 but not NaCl or KCl
interfered with the disruption of preassembled Akt:bArr2:PP2A
complexes by LiCl in vitro (Figure 4F). We then used purified
recombinant proteins to examine the impact of lithium and
magnesium on the Akt:bArr2 interaction. As previously shown
(Beaulieu et al., 2005), purified recombinant phospho-Akt1
directly and specifically interacts with a recombinant bArr2
tagged with glutathione S-transferase (GST) (Figure 4G). Purified
GST-bArr2 was incubated with the recombinant Akt1 in salt-free
buffer or in buffers containing either MgCl2, LiCl, or both salts.
Immunoprecipitation of recombinant Akt1 following these incu-
bations revealed that while Akt1 can form a complex with the re-
combinant GST-bArr2 in the presence of magnesium (20 mM),
this interaction fails to occur in salt-free buffer (Figure 4H). More-
over, addition of LiCl (50 mM) to the buffer containing magne-
sium also prevents the interaction of Akt and GST-bArr2
(Figure 4H). These results indicate that magnesium is a cofactor
for the interaction of Akt and bArr2. Furthermore, this suggests
that lithium competition with magnesium can affect not only
enzymatic activity but also the stability of higher-order protein
complexes, thus providing a potential mechanism for the desta-
bilization of the Akt:bArr2:PP2A complex by lithium.
No Effect of Lithium on Other b-arrestin
2-Mediated Functions
To address the general effect of lithium on bArr2-mediated
GPCR desensitization and signaling, we tested whether it would
interfere with the formation and cellular functions of other bArr2
protein complexes in vitro, in a cellular system, and in vivo. In
a first set of experiments, a recombinant Flag-bArr2 was ex-
pressed in human embryonic kidney cells (HEK293) and endog-
enous cellular proteins were coimmunoprecipitated with the
recombinant bArr2 in the presence or absence of lithium. As
shown (Figure 5A), addition of LiCl (20 mM) to the lysis buffer
did not destabilize the interactions of Flag-bArr2 with the known
bArr2 interaction partners (DeWire et al., 2007) clathrin, MDM2,
and Raf1. Furthermore, although the interactions of extracellular
signal-regulated kinase 1 (ERK1) and ERK2 with bArr2 were130 Cell 132, 125–136, January 11, 2008 ª2008 Elsevier Inc.somewhat reduced by lithium, these interactions were still
clearly detectable in buffers containing lithium concentrations
20 times greater then those sufficient to disrupt the Akt:
bArr2:PP2A signaling complex.
We then analyzed two well-documented bArr2 functions in
HEK293 cells—the stimulation of ERK2 following prolonged an-
giotensin receptor stimulation (Ahn et al., 2004) and the recruit-
ment of green fluorescent protein (GFP) tagged bArr2 to GPCRs
during receptor desensitization (Barak et al., 1997). Despite its
moderate effect on the interaction of bArr2 with ERK2, lithium
at concentrations as high as 100 mM did not interfere with
bArr2-mediated ERK2 stimulation (Figure 5B). Furthermore, lith-
ium had no significant effect on the recruitment of bArr2-GFP to
either angiotensin or D2 receptors upon stimulation in HEK293
cells (Figures 5C and 5D).
Finally, potential changes in receptor sensitivity in response
to lithium in vivo were assessed indirectly by measuring D2R
coupling to G proteins in brain tissue. Freshly dissociated stria-
tal pieces were pre-exposed to lithium (10 mM) in presence or
absence of millimolar concentrations of quinpirole for 15 min to
allow for activation and desensitization of D2Rs (Gainetdinov
et al., 1999). After this pre-exposure period, membranes were
prepared and assessed for [35S]GTPgS binding following D2R
stimulation with increasing concentrations of quinpirole
(Figure 5E). Under these conditions, pretreatment with quin-
pirole completely abolished agonist-stimulated binding of
[35S]GTPgS to membrane, suggesting that D2Rs had been
desensitized during pretreatment. Importantly, cotreatment of
striatal tissue with lithium had no effect on agonist-stimulated
binding of [35S]GTPgS to membrane prepared from either quin-
pirole-treated or nontreated tissue, thereby indicating that the
effect of lithium on the formation of the Akt:bArr2:PP2A com-
plex does not extend to all of bArr2 functions, such as receptor
desensitization.
b-arrestin 2 Is Essential for Responses
to Chronic Lithium
Since lithium is used chronically for therapy, we investigated the
effect of chronic lithium treatment in WT and bArr2-KO animals.
Mice were given lithium for 15 days following a protocol known to
produce clinically relevant serum lithium levels (see Supplemen-
tal Experimental Procedures and Table S1). Analysis of striatal
extracts from WT mice confirmed that chronic lithium treatment
enhances Akt and GSK3b phosphorylation in neuronal tissues
(Figures 6A and 6B). However, chronic lithium administration
did not influence Akt and GSK3b phosphorylation in bArr2-KO
mice (Figures 6A and 6B), thus showing that bArr2 is also essen-
tial for the regulation of these kinases following chronic lithium
treatment.
b-catenin is a component of the Wnt signaling pathway, which
is degraded following its phosphorylation by GSK3 (Orford et al.,
1997). Interestingly, chronic lithium treatment producing clini-
cally relevant serum levels also increases brain b-catenin levels
in rodents, thus providing a biochemical marker for the ability
of lithium to modulate GSK3 activity (De Ferrari et al., 2003). Fur-
thermore, overexpression of b-catenin has recently been shown
to phenocopy some behavioral outcomes of chronic lithium in
mice (Gould et al., 2007). To examine the possible contribution
Figure 5. Lack of Effect of Lithium on Various Other bArr2-Dependent Protein Interactions and Functions
(A) Lack of effect of LiCl on various bArr2 interactions in vitro. Nontreated, Flag-bArr2 or mock-transfected HEK293 cells were cultured in presence of serum and
lysed in buffer with or without LiCl (10 mM) 48 hr after transfection. Following Flag immunoprecipitation in the same buffer, coimmunoprecipitation of the known
bArr2 interaction partners, clathrin, MDM2, Raf1, ERK1, and ERK2, was determined.
(B) No effect of lithium on b-arrestin-mediated stimulation of ERK2 by angiotensin II (Ang). HEK293 cells stably expressing angiotensin II1a receptors (AT1aR)
were stimulated with 100 nM angiotensin II for 60 min in presence or absence of LiCl (10 or 100 mM in culture media for 12 hr prior and through the test) and
assayed for ERK2 phosphorylation (Thr202 and Tyr204) using western blot.
(C and D) Lithium does not affect bArr2 recruitment to activated GPCRs in HEK293 cells. Cells stably expressing the AT1aR (C) were transfected with bArr2-GFP
vectors and treated for 30 min with angiotensin II (100 nM) in the presence or absence of lithium (10 mM in culture media for 12 hr prior and through the test).
Alternatively (D), cells were cotransfected with bArr2-GFP and D2L DA receptor expression vectors and treated for 30 min with the D2 receptor agonists apo-
morphine (20 mM) or bromocryptine (20 mM) in the presence or absence of lithium. Internalization of receptors and bArr2-GFP recruitment was observed by con-
focal microscopy. White arrows indicate complexes of AT1aR:bArr2-GFP and D2LR:bArr2-GFP, respectively, in internalized vesicle (C) and plasma membrane
puncta (D) representative of class A and B GPCRs (Oakley et al., 2000); Scale bar: 10 mm.
(E) Effect of lithium on [35S]GTPgS binding to striatal membranes. WT mouse striatal pieces were incubated at 37C, 15 min in the presence or absence of 1 mM
quinpirole and LiCl (10 mM) prior to membrane preparation. [35S]GTPgS binding to membranes was determined after 60 min stimulation with quinpirole. Total
[35S]GTPgS binding is portrayed after subtracting unstimulated [35S]GTPgS binding from each point; data were analyzed by nonlinear regression. In the absence
of agonist stimulation, basal [35S]GTPgS binding values after preincubation were as follows: buffer only: 2560 ± 36; LiCl: 1980 ± 150; quinpirole: 2380 ± 180; LiCl +
quinpirole: 2040 ± 220 cpm. Data are means ± SEM, n = 4 mice per group.
For (A)–(D), all experiments were replicated at least three times.Cell 132, 125–136, January 11, 2008 ª2008 Elsevier Inc. 131
of bArr2 in the development of biochemical changes induced by
chronic lithium treatment, we measured striatal b-catenin levels
in bArr2-KO and WT littermates following chronic lithium admin-
Figure 6. bArr2 Is Required for Regulation of Akt/GSK3 Signaling in
Response to Chronic Lithium Administration
(A and B) Western blot and densitometric analysis of relative levels of phos-
pho-Thr308 Akt (A) and phospho-Ser9-GSK3b (B) in extracts prepared from
the striatum of WT or bArr2-KO mice following chronic lithium treatment
(0.12% in drinking water for 15 days). Representative western blots show re-
sults obtained from separate striatal extracts prepared from two individual
mice. For densitometric analysis, 10 mice per group were used. Total kinase
levels in extracts were used as loading controls for measurement of relative
phospho-protein levels.
(C and D) Western blot and densitometric analysis of relative levels of b-catenin
in extracts prepared from the striatum of WT or bArr2-KO mice following
chronic lithium treatment (n = 5 mice per group). b-actin was used as a loading
control.
(E) Tail suspension test in WT or bArr2-KO mice following chronic lithium treat-
ment. Behavior was scored as time spent in immobility (s) for the whole dura-
tion of the test (6 min) (n = 16–24 mice per group).
(F) Dark-light emergence test in WT and in bArr2-KO mice following chronic
lithium treatment. Behavior was scored as the latency to cross from the dark
to the light compartment of the test chamber (n = 8 mice per group).
Data are means ± SEM; ***p% 0.005; two-tailed Student’s t test was used for
analysis of western blots. One-way ANOVA with Bonferroni-corrected pairwise
comparisons was used for analysis of behavioral data.132 Cell 132, 125–136, January 11, 2008 ª2008 Elsevier Inc.istration. As might be expected, chronic treatment of WT mice
with lithium resulted in a marked increased of striatal b-catenin
levels (Figures 6C and 6D). In contrast, this same treatment
had no effect on the level of b-catenin in bArr2-KO mice
(Figures 6C and 6D), indicating the involvement of bArr2 in the
regulation of b-catenin by lithium.
To assess the role of bArr2 in the behavioral effects of chronic
lithium, we then tested chronically treated WT and bArr2-KO
mice in the tail suspension and dark-light emergence tests.
As shown (Figures 6E and 6F), chronic lithium administration
had a clear effect on both of these behavioral paradigms in
WT mice. However, lithium was not effective in either of these
tests in bArr2-KO mice (Figures 6E and 6F) thereby providing
additional evidence for the involvement of the Akt:bArr2:PP2A
signaling complex in the regulation of Akt/GSK3 signaling and
related behaviors in response to acute and chronic lithium
treatment.
DISCUSSION
The identification of G protein-independent GPCR signaling
mechanisms has introduced the notion that GPCRs can signal
simultaneously through distinct effector systems mediating sub-
sets of their actions (Beaulieu et al., 2005; Rajagopal et al., 2006).
Consequently, direct targeting of b-arrestin-mediated signaling
represents an appealing avenue for the development of drugs
acting on GPCR functions that may promote desired therapeutic
effects while avoiding undesired side effects associated with the
regulation of other signaling modalities (Beaulieu et al., 2007a;
DeWire et al., 2007). The results presented here provide direct
in vivo evidence that lithium exerts some of its biochemical
and behavioral effects by interfering with a b-arrestin signaling
complex involved in the regulation of Akt and GSK3b (Figure 7).
Under conditions compatible with its effects on mouse behav-
ior, lithium inhibits GSK3 indirectly by activating Akt (Beaulieu
et al., 2004; De Sarno et al., 2002). In living cells, overall Akt
activity results from an equilibrium between its phosphoryla-
tion/activation and dephosphorylation/inactivation (Figure 7).
Here we show that by disrupting the formation of the Akt:
bArr2:PP2A signaling complex that normally promotes Akt
dephosphorylation (Beaulieu et al., 2005), lithium shifts this equi-
librium toward the activated state, thereby resulting in increased
phosphorylation/inactivation of GSK3b (Figure 6). In bArr2-KO
mice that are unable to scaffold this signaling complex, lithium
fails to activate Akt, thus leading to a loss of indirect inhibition
of GSK3b by lithium and to a disruption of behavioral responses
to this pharmacological agent.
Our results identify the destabilization of b-arrestin-mediated
signaling complexes as a mechanism of action for a therapeuti-
cally effective drug, thereby providing an avenue for the develop-
ment of pharmacological agents acting on GPCR signaling. No-
tably, the disruption of the Akt:bArr2:PP2A signaling complex
occurs within a range of lithium concentrations (0.5 to 1.0 mM)
that is close to its clinically effective serum levels. This suggests
that lithium may exert some of its therapeutic action by regulat-
ing Akt/GSK3 signaling through disruption of a b-arrestin com-
plex (Figures 4 and 7). Although lithium is a direct inhibitor of
GSK3 (Klein and Melton, 1996), the relevance of this effect to
its therapeutic action has remained unclear mostly because of
the high Ki of lithium for this kinase (Phiel and Klein, 2001). How-
ever lithium also inhibits GSK3 indirectly through Akt activation
(Beaulieu et al., 2004; Chalecka-Franaszek and Chuang, 1999).
Multiple lines of in vivo evidence also support a role for Akt/
GSK3 signaling in the regulation of the amyloid precursor pro-
tein, tau, and b-catenin by lithium (Gould et al., 2007; O’Brien
Figure 7. Model for Akt-Mediated Indirect Inhibition of GSK3b by
Lithium
(A) Under basal conditions, Akt phosphorylation/activation and the conse-
quent GSK3b phosphorylation/inhibition are the result of an equilibrium be-
tween activation of Akt—by PI3K/PDK1-mediated phosphorylation—and its
inactivation—by PP2A-mediated dephosphorylation. Dephosphorylation of
Akt is facilitated by the formation of a signaling complex whereby bArr2 scaf-
folds Akt and PP2A in response to stimulation of GPCRs, such as the D2 DA
receptor.
(B) Lithium destabilizes the signaling complex formed by Akt, bArr2, and
PP2A, thereby enhancing Akt activity by reducing its dephosphorylation. In
turn, increased Akt activity results in a greater inhibition of GSK3b. In bArr2-
KO mice, lithium cannot act through this mechanism and GSK3b is not
inhibited.et al., 2004; Phiel et al., 2003). Furthermore, lithium affects the
regulation of the circadian clock by GSK3 (Yin et al., 2006) and
inhibition of GSK3b activity in the brain has been shown to repro-
duce behavioral correlates of lithium action (Beaulieu et al., 2004;
Gould et al., 2004; O’Brien et al., 2004).
Additional lines of evidence have also underscored the poten-
tial role of Akt/GSK3 signaling as a common molecular signal
integrator and therapeutic target for different classes of psychi-
atric drugs (Beaulieu, 2007). For instance, antidepressants as
well as typical and atypical antipsychotics have been shown to
increase GSK3b phosphorylation in mouse brain (Emamian
et al., 2004; Li et al., 2004, 2007). Interestingly, apart from its
use in the management of mood disorders, lithium is clinically
used to enhance the action of atypical antipsychotics and anti-
depressants in poorly responsive subjects (Valenstein et al.,
2006). Identification of the Akt:bArr2:PP2A signaling complex
as a molecular target of lithium thus provides a mechanism by
which this pharmacological agent may enhance the actions of
other drugs acting through Akt/GSK3 signaling by preventing
the inhibition of Akt by PP2A.
The evidence presented here provides a biochemical mecha-
nism that reconciles the effect of therapeutically effective lithium
concentrations with its action on Akt/GSK3 signaling. Further-
more, the discrepancy between the effect of lithium and TDZD-8
on locomotor activity in bArr2-KO mice (Figure 2) suggests
that indirect bArr2-dependent inhibition rather than direct
GSK3b inhibition by lithium mediates the effect of this agent, at
least on this behavioral paradigm. However it would be naive
to assume that lithium has a single mechanism of action, and it
is plausible that other mechanisms, such as the inhibition of ino-
sitol monophosphatases (Berridge et al., 1989), also contribute
to the pleiotropic effects of this pharmacological agent on
behavior. Furthermore while the action of lithium on Akt/GSK3
signaling is critical for at least some behavioral manifestations
in animal models, the relevance of our findings to the action of
lithium as a mood stabilizer in patients with bipolar disorder
remains to be further established.
In conclusion we have shown that lithium exerts at least some
of its behavioral effects through the disruption of a signaling
complex composed of Akt, PP2A, and bArr2. Importantly, lithium
destabilizes this complex without affecting other important func-
tions of bArr2 such as GPCR desensitization. These observa-
tions provide a mechanism by which lithium can modulate Akt/
GSK3 signaling and associated behaviors. Identification of this
mechanism of action for lithium may provide insight into the mo-
lecular mechanism of mood regulation and provide unexplored
research avenues to understand devastating human disorders
such as major depression and bipolar disorder. Furthermore,
the results presented here indicate that a pharmacologically
effective agent can exert its action by directly disrupting a bArr2
signaling complex rather than by interacting with a GPCR, thus
providing direct in vivo evidence for an additional type of phar-
macological intervention to regulate specific modalities of
GPCR signaling. Future investigations of such mechanism may
pave the way for the development of therapeutic agents not
only for the management of psychiatric disorders but also for
a host of other human pathologies involving the dysregulation
of GPCR signaling.Cell 132, 125–136, January 11, 2008 ª2008 Elsevier Inc. 133
EXPERIMENTAL PROCEDURES
Experimental Animals
bArr2-KO mice and gsk3b+/ were described previously (Bohn et al., 1999;
Hoeflich et al., 2000).
Drug Administration
For acute treatments, LiCl (Sigma-Aldrich, St. Louis, MO) was dissolved in sa-
line and injected (i.p.). For chronic treatments, LiCl was added to the drinking
water for a period of 15 days at a concentration of 0.12%. TDZD-8 (Calbio-
chem, Cambridge, MA) was injected (i.p.) after suspension in a minimal
amount of Tween and brought to volume with distilled water as described
(Beaulieu et al., 2004). The procedure for ICV injections has been described
previously (Beaulieu et al., 2005). Both LiCl and pbV (Phen) (Calbiochem)
were prepared in sterile artificial CSF (CMA Microdyalisis, N. Chelmsford, MA).
Western Blot Analysis
Western blot analyses were performed as described (Beaulieu et al., 2004).
Samples were homogenized in boiling 1% SDS solution supplemented with
2 mM okadaic acid. Protein extracts (25 or 50 mg) were separated on 10%
SDS/PAGE and transferred to nitrocellulose membranes. Blots were immuno-
stained overnight at 4C with primary antibodies. Immune complexes were
detected using appropriate peroxidase-conjugated secondary antibodies
along with a chemiluminescent reagent.
Immunoprecipitations from Cells and Brain Tissue
Tissue was homogenized at 4C in 200 ml lysis buffer (10 mM Tris-HCl [pH 7.4],
1.0% Triton X-100) containing a cocktail of protease inhibitors (Sigma-Aldrich)
and various concentrations of salts. Immunoprecipitations were conducted
overnight at 4C. For interaction studies in cells, HEK293 cells were transiently
transfected with a vector expressing recombinant human Flag-bArr2 or with
empty vector and cultured in presence of fetal calf serum for 48 hr post-trans-
fection. Cells were rinsed in PBS, scraped, and incubated for 1 hr at 4C in lysis
buffer with or without LiCl (10 mM) prior to overnight immunoprecipitation in
the same buffer with anti-Flag Sepharose beads (GE-Healthcare Life Sciences)
at 4C.
Protein:Protein Interaction on Recombinant Proteins
The construct expressing GST-bArr2 recombinant proteins and the protocol
used for GST protein production and affinity purification have been described
previously (Beaulieu et al., 2005). To evaluate the impact of different salts on
the formation of the Akt:bArr2 protein complex, GST-bArr2 was produced in
a recombinant bacterial system and purified by affinity purification. Purified
GST-bArr2 was adjusted to a concentration of 1 mg/ml in ice-cold Tris-HCl
(10 mM, pH 7.4) plus protease inhibitors. Recombinant GST-bArr2 (20 mg)
was incubated for 8 hr at 4C along with phospho-Akt1 (2 mg) in 1 ml of assay
buffer (Tris-HCl [10 mM, pH7.4], okadaic acid [2 mM], and protease inhibitors)
containing different concentrations of LiCl and MgCl2.
Measurement of bArr2 Function in Cells
HEK293 cells were maintained and transfected as described (Marion et al.,
2004). Confocal microscopy was performed on Flag-AT1aR-tagged HEK293
cells transiently transfected with bArr2-GFP as described (Barak et al.,
1997). Alternatively cells were transiently transfected with vectors expressing
bArr2-GFP and the human D2L dopamine receptor (Kim et al., 2001). For lith-
ium and receptor agonist treatments, cells were serum-starved overnight, ex-
posed to LiCl (10 or 100 mM), and stimulated 5 min later with 100 nM angioten-
sin II, 20 mM apomorphine, or 20 mM bromocryptine for either 30 or 60 min.
Agonist-Stimulated [35S]GTPgS Binding
Experiments were carried out as described (Gainetdinov et al., 1999). Briefly,
tissue pieces were incubated in the presence or absence of 1 mM quinpirole
and/or 10 mM LiCl in 1 ml of lysis buffer (20 mM HEPES [pH 7.4], 100 mM
NaCl, 2 mM MgCl2, 1 mM EDTA, 1 mM DTT) per sample for 15 min at 37
C.
Samples were then placed on ice and homogenized. Homogenates were
centrifuged at 1000 rpm for 10 min at 4C. Supernatant was further centrifuged
at 13,000 rpm for 30 min at 4C. The pellet was suspended in assay buffer134 Cell 132, 125–136, January 11, 2008 ª2008 Elsevier Inc.(20 mM HEPES [pH 7.4], 150 mM NaCl, 2 mM MgCl2, GDP 100 Mm). Mem-
brane fractions (20 mg each point) were incubated at 30C for 1 hr together
with [35S]GTPgS (0.02 nM) and different concentrations of quinpirole in a range
between 1 mM and 10 nM. Incubation mixture (total volume of 200 ml) was
filtered through Brandel GF/B glass filters, washed three times with 10 mM
Tris-HCl (pH 7.4), and bound radioactivity determined by liquid scintillation
spectrometry.
Measurement of Locomotor Activity
Mice were injected with vehicle (10 ml/kg body weight, i.p.) or drug, placed into
the open field, and monitored for 1 hr after injection. Locomotor activity was
measured in terms of the total distance traveled (horizontal activity) as de-
scribed (Beaulieu et al., 2004).
Tail Suspension Test and Dark-Light Emergence Test
For the tail suspension test, mice were tested for 6 min in a tail suspension ap-
paratus (Med-Associates, St. Albans, VT) as described (Crowley et al., 2004).
The dark-light box emergence test was performed for a duration of 5 min with
mice initially placed at the center of the dark chamber, as described (Weis-
staub et al., 2006; Welch et al., 2007).
Statistical Analysis
The data are presented as means ± SEM. Data from western blot were ana-
lyzed by two-tailed t test or ANOVA; behavioral data were evaluated by
t test or repeated-measures ANOVA or one-way ANOVA followed by Bonfer-
roni-corrected pairwise comparisons. A p < 0.05 was considered significant.
Detailed description of experimental procedures and materials are available
as Supplemental Data.
Supplemental Data
Supplemental Data contain Experimental Procedures and one table and can
be found with this article online at http://www.cell.com/cgi/content/full/
132/1/125/DC1/.
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